Home / Pharmaceutical company intelligence
Mass Pharma (Pvt) Ltd. logo
Pharmaceutical company intelligence

Mass Pharma (Pvt) Ltd.

Private pharmaceutical manufacturer · Lahore · Pakistan

Lahore-based national pharmaceutical manufacturer and marketer with domestic and international operations.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date20 Aug 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Mass Pharma (Private) Limited
Company type
Private pharmaceutical manufacturer
Address
17-KM Ferozepur Road, Lahore, Pakistan
Phone
+92 42 35824881-4; +92 322 4873081
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000444 Mass Pharma (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000444 120 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx122public portfolio records represented
REG107unique registrations represented
IDX64indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR119current validated price records
G59generic molecules in indexed catalogue
DF10dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage90%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMass Pharma (Pvt) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mass-pharma-pvt-ltdGenerated 23 Sep 2026Anti-infectives66 · 55%Cardiovascular22 · 18%CNS & mental health9 · 8%Hematology & thrombosis7 · 6%Vitamins, minerals & nutrition6 · 5%Dermatology4 · 3%Oncology & immunology2 · 2%Other therapeutic areas4 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMass Pharma (Pvt) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mass-pharma-pvt-ltdGenerated 23 Sep 2026120presentationsTablet50 · 42%Injection24 · 20%Capsule14 · 12%Cream14 · 12%Infusion6 · 5%Suspension4 · 3%Other forms8 · 7%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMass Pharma (Pvt) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mass-pharma-pvt-ltdGenerated 23 Sep 2026108comparable productsBelow peer median31 · 29%Near peer median28 · 26%Above peer median49 · 45%Company median price position+4.8%Lowest-price equivalents13Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMass Pharma (Pvt) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mass-pharma-pvt-ltdGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,34 shared58% overlapAtco Laboratories Limited33 shared56% overlapCCL Pharmaceuticals (Pvt.) Limited32 shared54% overlapZafa Pharmaceutical Laboratories (P…32 shared54% overlapValor Pharmaceuticals31 shared53% overlapM/s. Genix Pharma (Pvt) Ltd.30 shared51% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives66 products · 55%
Cardiovascular22 products · 18%
CNS & mental health9 products · 8%
Hematology & thrombosis7 products · 6%
Vitamins, minerals & nutrition6 products · 5%
Dermatology4 products · 3%
Oncology & immunology2 products · 2%
Respiratory & allergy2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antifungals15 products · 13%
Third-generation cephalosporins10 products · 8%
Calcium-channel blockers9 products · 8%
Fluoroquinolone antibacterials8 products · 7%
First-generation cephalosporins7 products · 6%
Vitamins / minerals / hematinics6 products · 5%
Aminoglycoside antibacterials5 products · 4%
Angiotensin receptor blockers4 products · 3%
Formulation footprint

Dosage forms

Tablet50 products
Injection24 products
Capsule14 products
Cream14 products
Infusion6 products
Suspension4 products
Gel3 products
Lotion2 products
Ointment2 products
Drops1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 AmodipAmlodipine 5presentations 10 mg, 2.5 mg, 5 mg · Tablet #2 MaclexinCephalexin 5presentations 125 mg, 125 mg/5 mL, 250 mg, 250 mg/5 mL · Drops, Suspension, Capsule #3 MinkAmikacin 5presentations 100 mg, 25 mg, 250 mg, 50 mg · Injection #4 AnabactMetronidazole (Benzoate) 3presentations 0.75 % · Gel #5 De-Nile PlusTelmisartan + Hydrochlorothiazide 3presentations 20 mg + 12.5 mg, 40 mg + 12.5 mg, 80 mg + 12.5 mg · Tablet #6 DinaphinCeftriaxone 3presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3129% of comparable products
Near market median28within ±5% of median
Above market median4945% of comparable products
Lowest-price equivalents13ties included
Company median price position +4.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Grow-D 5 mgCholecalciferol · Injection · 1mlx10 PKR 74.33/mL-60.3% vs market median Amorin 50 mgAzathioprine · Tablet · 1x10 PKR 13.95/tablet-49.5% vs market median Spril 100 mg/5 mLCefixime · Suspension · 60ml PKR 5.85/mL-44.2% vs market median Maclexin 250 mg/5 mLCephalexin · Suspension · 60ml PKR 2.16/mL-34.5% vs market median Zedopa CR 25 mg + 250 mgCarbidopa + Levodopa · Tablet · 10x10 PKR 13.17/tablet-29.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 34shared generics Atco Laboratories Limited278 products · 94 generics 33shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 32shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 32shared generics Valor Pharmaceuticals219 products · 97 generics 31shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 30shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers106Distinct registrations among indexed, published, presentation-validated products only
Verified price observations239
Products with a verified price120
Products with multiple price observations119
Source records with multiple versions120
Latest portfolio source check22 Sep 2026
Latest effective price date20 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

107 unique registration(s) · 64 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Adoxa Doxycycline 100 mg Tablet 3x10 024378 PKR 291.21 PKR 9.71/tablet 22% above median
Anabact Metronidazole (Benzoate) 0.75 % Gel 5gm 027692 PKR 239.08 PKR 47.82/g 340% above median
Anabact Metronidazole (Benzoate) 0.75 % Gel 15gm 027692 PKR 398.46 PKR 26.56/g 145% above median
Anabact Metronidazole (Benzoate) 0.75 % Gel 30gm 027692 PKR 478.15 PKR 15.94/g Near median
Cefax Cefotaxime 250 mg Injection 1x1 024261 PKR 110.89 PKR 110.89/vial/unit 5% above median
Cefax Cefotaxime 1 g Injection 1x1 027132 PKR 300.58 PKR 300.58/vial/unit Near median
Cefazid Ceftazidime 250 mg Injection 1x1 024177 PKR 167.85 PKR 167.85/vial/unit Near median
Cefazid Ceftazidime 1 g Injection 1x1 027130 PKR 479.57 PKR 479.57/vial/unit Near median
Dinaphin Ceftriaxone 250 mg Injection 1x1 024258 PKR 247.84 PKR 247.84/vial/unit 29% above median
Dinaphin Ceftriaxone 1 g Injection 1x1 027124 PKR 595.63 PKR 595.63/vial/unit Near median
Dinaphin Ceftriaxone 500 mg Injection 1x1 030876 PKR 351.10 PKR 351.10/vial/unit 8% above median
Dipcort Miconazole + Hydrocortisone 2% + 1% Cream 15gm 027129 PKR 130.02 PKR 8.67/g 18% below median
Entawin Entecavir 0.5 mg Tablet 3x10 069489 PKR 21,357.57 PKR 711.92/tablet 100% above median
Ezonex Azithromycin 250 mg Capsule 2x5 026672 PKR 544.41 PKR 54.44/capsule 10% above median
Ezonex Azithromycin 250 mg Capsule 1x6 026672 PKR 326.65 PKR 54.44/capsule 10% above median
Ezonex Azithromycin 500 mg Tablet 1x6 106148 PKR 412.69 PKR 68.78/tablet 19% below median
Favrizol Fluconazole 150 mg Capsule 1x4 026123 PKR 1,510.41 PKR 377.60/capsule 44% above median
H-Masquine Hydroxychloroquine 200 mg Tablet 30's 102285 PKR 334.58 PKR 11.15/tablet 23% below median
Hitroxin Ciprofloxacin 200 mg IV infusion 100ml 025442 PKR 638.18 PKR 6.38/mL 198% above median
Hitroxin Ciprofloxacin 250 mg IV infusion 1x10 029441 PKR 268.49 PKR 26.85/vial/unit 21% above median
Hitroxin Ciprofloxacin 500 mg IV infusion 1x10 029442 PKR 520.46 PKR 52.05/vial/unit 28% above median
Itranex Itraconazole 100 mg Capsule 1x4 030877 PKR 513.00 PKR 128.25/capsule 12% below median
Levite Levofloxacin 250 mg IV infusion 1x10 032310 PKR 516.33 PKR 51.63/vial/unit No comparator
Levite Levofloxacin 500 mg IV infusion 1x10 032311 PKR 859.17 PKR 85.92/vial/unit No comparator
Levite Levofloxacin 500 mg IV infusion 100ml 038343 PKR 1,445.71 PKR 14.46/mL 180% above median
Lopi-Mass Lopinavir + Ritonavir 50 mg + 50 mg Tablet 12x10 106147 PKR 11,525.21 PKR 96.04/tablet 19% below median
Lotricort Betamethasone + Clotrimazole 0.05 % + 1.0 % Cream 15gm 030873 PKR 162.09 PKR 10.81/g Near median
Lotricort Betamethasone Dipro Clotrimazole 0.05 % Cream 10gm 030873 PKR 93.82 PKR 9.38/g Near median
Lotricort-G Betamethasone + Clotrimazole 1 % + 0.1 % Cream 15gm 041697 PKR 151.42 PKR 10.09/g No comparator
Lotricort-G Betamethasone Clotrimazole 0.05 % Cream 10gm 041697 PKR 82.30 PKR 8.23/g 18% below median
Lotrigen Clotrimazole 1% Cream 15gm 030869 PKR 88.27 PKR 5.88/g Near median
Lotrigen HC Clotrimazole 1 % Cream 10gm 062885 PKR 127.96 PKR 12.80/g 107% above median
Lumifal Artemether + Lumefantrine 20 mg + 120 mg Tablet 2x8 054481 PKR 510.03 PKR 31.88/tablet 20% below median
Lumifal Plus Artemether + Lumefantrine 40 mg + 240 mg Tablet 1x8 054482 PKR 420.78 PKR 52.60/tablet 18% below median
Maclexin Cephalexin 250 mg Capsule 1x10 020866 PKR 111.99 PKR 11.20/capsule 29% below median
Maclexin Cephalexin 500 mg Capsule 1x10 020867 PKR 224.99 PKR 22.50/capsule 27% below median
Maclexin Cephalexin 125 mg/5 mL Suspension 60ml 020868 PKR 80.49 PKR 1.34/mL 28% below median
Maclexin Cephalexin 250 mg/5 mL Suspension 60ml 020869 PKR 129.43 PKR 2.16/mL 34% below median
Maclexin Cephalexin 125 mg Oral drops 10ml 022392 PKR 88.65 PKR 8.87/mL No comparator
Malin Permethrin 5% Lotion 120ml 048052 PKR 330.06 PKR 2.75/mL Near median
Malin Permethrin 5 % Lotion 60ml 048052 PKR 165.22 PKR 2.75/mL 5% above median
Massvir Oseltamivir 75 mg Capsule 10's 110664 PKR 1,059.50 PKR 105.95/capsule 12% below median
Mectimite Ivermectin 3 mg Tablet 2x10 057558 PKR 660.90 PKR 33.05/tablet Near median
Mectimite Ivermectin 6 mg Tablet 1x10 057559 PKR 547.31 PKR 54.73/tablet Near median
Mink Amikacin 100 mg Injection 2mlx1 035502 PKR 84.68 PKR 42.34/mL Near median
Mink Amikacin 250 mg Injection 2mlx1 035503 PKR 136.31 PKR 68.16/mL Near median
Mink Amikacin 500 mg Injection 2mlx1 035504 PKR 231.31 PKR 115.66/mL Near median
Mink Amikacin 25 mg Injection 1mlx1 037730 PKR 41.31 PKR 41.31/mL 11% below median
Mink Amikacin 50 mg Injection 1mlx1 037731 PKR 51.63 PKR 51.63/mL 16% above median
Mobik Moxifloxacin 400 mg Tablet 1x5 035820 PKR 994.59 PKR 198.92/tablet 8% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Mass Pharma (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/mass-pharma-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.